Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Regenerx Biopharmaceuticals RGRX

Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.


Recent & Breaking News (OTCQB:RGRX)

RegeneRx Partner Receives Canadian Patent For Treatment of Peripheral Neuropathy

PR Newswire February 13, 2020

RegeneRx Partner Updates on Phase 3 Dry Eye Trial

PR Newswire February 3, 2020

RegeneRx Publishes Annual Letter to Shareholders

PR Newswire January 22, 2020

RegeneRx Partner Receives Patent for Reducing Diabetic-Induced Vascular Dysfunction in Korea

PR Newswire January 21, 2020

RegeneRx's T?4 Significantly Reduces Damage in Ischemic Acute Kidney Injury Model

PR Newswire November 18, 2019

RegeneRx's T?4 Promotes Autophagy and Repair in Chronic Granulomatous Disease Model

PR Newswire November 14, 2019

RegeneRx JV Partner Updates on Strategic Dry Eye Discussions

PR Newswire October 16, 2019

RegeneRx Partner Updates on ARISE-3 Clinical Trial

PR Newswire September 30, 2019

RegeneRx to Present at Fall Investor Summit on September 17

PR Newswire September 10, 2019

RegeneRx Modifies September Conference Schedule

PR Newswire September 4, 2019

First Patient Enrolled in RGN-137 Trial for Epidermolysis Bullosa Experiences Complete Wound Healing

PR Newswire August 5, 2019

RegeneRx's RGN-137 for Epidermolysis Bullosa Subject of New Article in Seeking Alpha Investor Site

PR Newswire July 29, 2019

RegeneRx to Present at the Rodman & Renshaw and the Fall Investor Summit Conferences in September 2019

PR Newswire July 16, 2019

RegeneRx Licensee Administers RGN-137 to First Patient in Phase 2 EB Clinical Trial

PR Newswire May 29, 2019

RegeneRx Receives Final Payment from Convertible Debt Financing

PR Newswire May 28, 2019

RegeneRx Partner Receives Patent for New Ophthalmic Formulation of Thymosin Beta 4

PR Newswire May 16, 2019

First Patient Enrolled in RegeneRx JV Phase 3 Dry Eye Trial

PR Newswire May 13, 2019

RegeneRx Publishes Annual Letter to Shareholders

PR Newswire April 22, 2019

RegeneRx to Present at 2019 Spring Investor Summit

PR Newswire March 27, 2019

RegeneRx and Lee's Pharm to Accelerate RGN-259 Development in China

PR Newswire March 26, 2019